HKEX: 9606
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
View original source (HKEXnews)
Earlier from Duality Biotherapeutics
- Next Day Disclosure Return
- 2026 Interim report
- DualityBio Announces China NMPA Acceptance of Biologics License Application Seeking Approval for Trastuzumab Pamirtecan for the Treatment of Unresectable or Metastatic HER2-Positive Adult Breast Cancer
- DualityBio (9606.HK) Announces 2025 Annual Results